DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The Safety of Proctofoam-HC in the Third Trimester of Pregnancy

Information source: The Hospital for Sick Children
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hemorrhoids; Pregnancy

Intervention: Proctofoam-HC® (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: The Hospital for Sick Children

Official(s) and/or principal investigator(s):
Gideon Koren, MD, Principal Investigator, Affiliation: The Hospital for Sick Children, Toronto Canada


The purpose of this study is to evaluate the fetal safety of topical application of Proctofoam-HC, an antihemorrhoidal, in the third trimester of pregnancy.

Clinical Details

Official title: The Safety of Proctofoam-HC in the Third Trimester of Pregnancy

Study design: Observational Model: Case Control, Time Perspective: Prospective

Primary outcome: Birth-weight

Secondary outcome:

Gestational Age at Delivery

Mode of Delivery


Fetal Distress

Low Birth Weight at Birth

Neonatal Health

Detailed description: Hemorrhoids are a frequent condition in pregnancy. The rate is increased as pregnancy progresses, and they affect up to 24% of pregnant women in the third trimester. Complications of untreated hemorrhoids include bleeding, prolapse, soiling, discharge with perianal irritation and itching, and in severe cases, severe pain and venous engorgement which could even lead to thrombosis and infarction. Hemorrhoids are treated with a variety of suppositories and gels, based on analgesic and anti-inflammatory effects. The safety of these antihemorrhoidal products has not yet been documented in pregnant women. Proctofoam-HC® has been on the Canadian market for 25 years. It combines the anti-inflammatory action of hydrocortisone with the surface anesthetic effect of pramoxine HCl. It is approved for temporary relief of anorectal inflammation, pruritus, pain and swelling associated with haemorrhoids, fissures, pruritus ani, cryptitis, proctitis and postoperative pain. We hypothesize that local application of Proctofoam-HC® in the third trimester of pregnancy is safe for the mother and fetus.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.


Inclusion Criteria:

- For intervention group, any pregnant woman with a primary anorectal condition during

the third trimester of pregnancy

- For control group, women in third trimester of pregnancy not treated with Proctofoam,

and matched on maternal age and smoking status

- for either group,no other pregnancy complications

Exclusion Criteria:

- exposure to known teratogens during pregnancy as evident either during the prenatal

or postnatal interview

- insufficient English language skills to understand the questionnaires and assessment


- Women who have received other corticosteroid medications (systemic or topical)during


- Women with the following conditions: abscess, fistula, tuberculosis, varicella, acute

Herpes Simplex or fungal infection

- age less than 18 years

- History of previous reaction to any of the product's components, such as: local

irritation, hypertrichosis, hypopigmentation, etc.

- Known Intrauterine Growth Restriction (IUGR) or a chronic state that may cause IUGR

(SLE, placental insufficiency).

- Multi fetal pregnancy

- Binge alcohol consumption (5 or more drinks on one occasion,in a row or within a

short period of time)

Locations and Contacts

Mount Sinai Hospital, Toronto, Ontario M5G 1X5, Canada

The Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada

Additional Information

Starting date: November 2006
Last updated: January 3, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017